Analysis
The pattern across Value Add Pulse's own coverage this month is consistent: small, clinical-stage biotech IPOs keep clearing the market while larger, capital-intensive listings stall. The recent sequence:
- TRexBio -- closed a $116.7M IPO on Oct. 13
- Retension Pharmaceuticals -- priced a $45M IPO the same week (combined $161.7M with TRexBio)
- Firmus -- withdrew a roughly $31B-valuation listing on market-turbulence grounds days earlier
- Iambic Therapeutics -- raised its own IPO target from about $100M to $150M, a rare upward revision
- City Therapeutics -- set terms for a roughly $175M Nasdaq IPO (9.7M shares at $17-$19), trading expected to start Oct. 16 under ticker CTY, the fourth clinical-stage biotech to price in roughly two weeks
“The window currently open rewards near-term, binary clinical catalysts at valuations in the hundreds of millions, not thousand-times-revenue infrastructure bets.”
Pulse argued earlier this week that public markets are pricing small, clinical-stage biotech IPOs fine while larger tech and infrastructure listings like Firmus still can't clear; this week's pricings extend that pattern rather than reverse it. Against Pulse's own tracker of $184.5 billion in venture funding across 3,399 stories and a $140 million median disclosed round, these IPOs are modest even by private-market standards -- which is itself the point. The window currently open rewards near-term, binary clinical catalysts at valuations in the hundreds of millions, not thousand-times-revenue infrastructure bets. Whether that window widens heading into 2027 depends on whether a tech or AI-infrastructure name successfully prices before another Firmus-sized withdrawal resets sentiment again.
